INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,683,172 | -16.7% | 211,359 | +7.4% | 0.18% | -14.2% |
| Q2 2023 | $8,026,320 | +14.3% | 196,820 | +4.5% | 0.20% | +7.9% |
| Q1 2023 | $7,020,929 | +15.9% | 188,380 | +8.5% | 0.19% | +9.9% |
| Q4 2022 | $6,058,858 | -32.7% | 173,656 | +1.0% | 0.17% | -38.4% |
| Q3 2022 | $9,000,000 | +3.9% | 171,854 | +2.7% | 0.28% | +7.3% |
| Q2 2022 | $8,661,000 | +40.4% | 167,326 | +97.0% | 0.26% | +53.8% |
| Q1 2022 | $6,171,000 | -34.4% | 84,921 | +6.8% | 0.17% | -32.9% |
| Q4 2021 | $9,405,000 | +58.5% | 79,543 | +79.8% | 0.25% | +43.2% |
| Q3 2021 | $5,935,000 | +1645.6% | 44,245 | +2006.9% | 0.18% | +1660.0% |
| Q2 2021 | $340,000 | -89.2% | 2,100 | -98.1% | 0.01% | -94.7% |
| Q3 2018 | $3,155,000 | +6.9% | 110,239 | +2.2% | 0.19% | +5.6% |
| Q2 2018 | $2,952,000 | +29.1% | 107,912 | -0.5% | 0.18% | +29.9% |
| Q1 2018 | $2,287,000 | +17.5% | 108,425 | +7.1% | 0.14% | +20.2% |
| Q4 2017 | $1,946,000 | – | 101,230 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |